

Fevzi F Yalniz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8889901/publications.pdf>

Version: 2024-02-01

18
papers

443
citations

840585

11
h-index

887953

17
g-index

19
all docs

19
docs citations

19
times ranked

803
citing authors

#	ARTICLE	IF	CITATIONS
1	CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. <i>Blood Advances</i> , 2021, 5, 2799-2806.	2.5	57
2	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 689-695.	0.6	14
3	A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. <i>British Journal of Haematology</i> , 2020, 188, 404-412.	1.2	9
4	Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1759-1769.	2.0	9
5	Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. <i>Cancer</i> , 2020, 126, 2183-2192.	2.0	17
6	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleuce (axi-cel) for Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 17-18.	0.6	1
7	Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. <i>Drugs</i> , 2019, 79, 1287-1304.	4.9	22
8	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766.	2.0	38
9	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	2.0	32
10	Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1920-1927.	2.0	40
11	Therapy related chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. <i>American Journal of Hematology</i> , 2018, 93, 65-73.	2.0	49
12	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. <i>Leukemia</i> , 2018, 32, 2512-2518.	3.3	26
13	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. <i>EBioMedicine</i> , 2018, 31, 174-181.	2.7	72
14	Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1478-1484.	2.0	31
15	Feasibility of Allogeneic Hematopoietic Stem Cell Transplant for High Risk FLT3-ITD Mutant Patients with Acute Myeloid Leukemia in CR1- a Real World Analysis. <i>Blood</i> , 2016, 128, 4694-4694.	0.6	1
16	Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 4593-4593.	0.6	0
17	Severe odynophagia in a patient developing after azithromycin intake: a case report. <i>Cases Journal</i> , 2010, 3, 48.	0.4	8
18	Chronic Cigarette Smoking Affects Left and Right Ventricular Long-Axis Function in Healthy Young Subjects: A Doppler Myocardial Imaging Study. <i>Echocardiography</i> , 2009, 26, 1019-1025.	0.3	15